Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2430
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant cancer with limited treatment options. Chimeric antigen receptor T cells (CAR‐T) are genetically engineered T cells that can specifically kill tumor cells without major histocompatibility complex restriction.… read more here.
Keywords: car therapy; car; pancreatic ductal; ductal adenocarcinoma ... See more keywords
MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinoma
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2733
Abstract: The modification of chimeric antigen receptor (CAR) endowing T cells with tumor‐specific cytotoxicity induces antitumor immunity. However, the structural characteristics of solid tumors, the loss of specific antigens, and the strong immunosuppressive environment are challenges… read more here.
Keywords: neck squamous; muc1; car; car therapy ... See more keywords
In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development.
Sign Up to like & getrecommendations! Published in 2020 at "Methods in molecular biology"
DOI: 10.1007/978-1-0716-0146-4_7
Abstract: Chimeric antigen receptor (CAR) cancer immunotherapy uses autologous immune system's cells, genetically modified, to reinforce the immune system against cancer cells. Genetic modification is usually mediated via viral transfection, despite the risk of insertional oncogenesis… read more here.
Keywords: transcribed ivt; ivt mrna; car; car therapy ... See more keywords
Neurological updates: neurological complications of CAR-T therapy
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Neurology"
DOI: 10.1007/s00415-020-10237-3
Abstract: Chimeric antigen receptor (CAR)-expressing T cells now offer an effective treatment option for people with previously refractory B cell malignancies and are under development for a wide range of other tumours. However, neurological toxicity is… read more here.
Keywords: neurological updates; car; updates neurological; neurological complications ... See more keywords
Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Hematology"
DOI: 10.1007/s12185-021-03213-8
Abstract: The scientific concept of genetically endowing T cells with target-specific tumoricidal activity using antibody-mediated antigen recognition was first described by Dr. Eshhar around 1990 [1]. Such engineered T cells, which were originally called “T-bodies”, are… read more here.
Keywords: potential car; efforts maximize; car; maximize potential ... See more keywords
Clinical Outcomes of CLL Patients with Relapsed or Refractory Disease after CD19-Specific CAR-T Therapy
Sign Up to like & getrecommendations! Published in 2020 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2019.12.622
Abstract: Background Chimeric antigen receptor T-cell (CAR-T) therapy has shown promising efficacy in high-risk CLL but progressive disease after CAR-T is not uncommon. We studied outcomes of pts with relapsed or refractory CLL after CAR-T to… read more here.
Keywords: relapsed refractory; disease; car; progression ... See more keywords
Standardizing CAR-T therapy: Getting it scaled up.
Sign Up to like & getrecommendations! Published in 2019 at "Biotechnology advances"
DOI: 10.1016/j.biotechadv.2018.12.002
Abstract: CAR-T therapy, grafting the specificity of a monoclonal antibody onto a T cell to target certain cancer cells, has been recognized as a promising therapeutic approach for cancer control as evidenced by the two CAR-T… read more here.
Keywords: standardizing car; getting scaled; therapy getting; car ... See more keywords
Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer letters"
DOI: 10.1016/j.canlet.2020.05.013
Abstract: Chimeric antigen receptor T (CAR-T) therapy faces at least two major obstacles in solid tumors, including to find specific antigen among the heterogeneous tumor mass and to overcome the inhibitory microenvironment. Developing novel strategies to… read more here.
Keywords: solid tumors; tumor tagging; antigen; car ... See more keywords
PH-0329 Feasibility and outcome of bridging RT pre CAR-T in DLBCL in one centre with a wide referral network
Sign Up to like & getrecommendations! Published in 2021 at "Radiotherapy and Oncology"
DOI: 10.1016/s0167-8140(21)07302-3
Abstract: Purpose or Objective CD19 CAR-T therapy is the most effective salvage treatment for relapsed/refractory DLBCL. However the manufacture of CAR-T cells takes several weeks and patients (pts) are at risk of progression during this time… read more here.
Keywords: dlbcl; infusion; toxicity; car ... See more keywords
Second anticancer CAR T therapy receives FDA approval
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Drug Discovery"
DOI: 10.1038/nrd.2017.249
Abstract: The approval of axicabtagene ciloleucel was based on a 101‐patient pivotal trial, which showed third‐line use of the therapy resulted in an objective response rate of 72% and a complete remission rate of 51% in… read more here.
Keywords: anticancer car; approval; car; car therapy ... See more keywords
Hit and Run: Bilateral Massive Intraocular Lymphomatous Infiltration after CAR-T Therapy.
Sign Up to like & getrecommendations! Published in 2023 at "Ocular immunology and inflammation"
DOI: 10.1080/09273948.2023.2191713
Abstract: PURPOSE We report a case of bilateral intraocular infiltration of DLBCL after CAR-T therapy. METHODS Retrospective case report. RESULTS A 62-year-old Caucasian male with medical history of high-grade DLBCL presented with papillitis and vitritis upon… read more here.
Keywords: infiltration; car therapy; run bilateral; car ... See more keywords